

The Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A formulation comprising at least one hybridoma having at least one first cell fused to at least one second cell; wherein said first cell is an antigen presenting cell selected from the group consisting of a macrophage and a dendritic cell, and said second cell is a virally infected cell.
2. (Previously Presented) The formulation of claim 1, wherein said dendritic cells are selected from the group consisting of cutaneous epidermal Langerhans cells, dermal dendritic cells, lymph node dendritic cells, spleen dendritic cells and dendritic cells derived through in vitro culture of precursors.
3. (Canceled).
4. (Previously Presented) The formulation of claim 1, wherein said virally infected cells are selected from the group consisting of cells infected with influenza virus, human immunodeficiency virus, cytomegalo virus, human papilloma virus and herpes simplex virus.
5. (Previously Presented) The formulation of claim 1, wherein said hybridoma contains a ratio of first cells to second cells between about 1:100 and 100:1.
6. (Previously Presented) The formulation of claim 1, wherein said hybridoma contains a ratio of first cells to second cells of between about 1:10 and 10:1.
7. (Previously Presented) The formulation of claim 1, wherein said hybridoma contains a ratio of first cells to second cells of about 6:1.

8. (Previously Presented) A pharmaceutical composition comprising: at least one hybridoma; and a suitable pharmaceutical carrier; wherein each hybridoma is comprised of at least one first cell fused to at least one second cell; wherein said first cell is an antigen presenting cell selected from the group consisting of a macrophage and a dendritic cell, and said second cell is a virally infected cell.

9. (Previously Presented) The pharmaceutical composition of claim 8, wherein said suitable pharmaceutical carrier is selected from the group consisting of saline and phosphate buffered saline.

10. (Previously Presented) The pharmaceutical composition of claim 8, wherein said hybridomas have a ratio of first cells to second cells of between about 1:100 and 100:1.

11. (Previously Presented) The pharmaceutical composition of claim 8, wherein said hybridomas have a ratio of first cells to second cells of between about 1:10 and 10:1.

12. (Previously Presented) The pharmaceutical composition of claim 9, wherein said hybridomas have a ratio of first cells to second cells of about 6:1.

13-36. (Canceled).